Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004081 · ClinicalTrials.gov registry record · Phase 2
Docetaxel in Treating Women With Ovarian Epithelial or Primary Peritoneal Cancer
A Phase 2 study, sponsored by Beth Israel Deaconess Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT00004081 is a Phase 2 study that has completed, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 30 participants.
The verdict
NCT00004081, a Phase 2 study, has completed, sponsored by Beth Israel Deaconess Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of docetaxel in treating women who have ovarian epithelial cancer or primary peritoneal cancer that has not responded to previous treatment.
Interventions
- DRUG docetaxel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 1999-07 |
| Est. Completion | 2003-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00004081
The ClinicalTrials.gov registry entry for NCT00004081 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Beth Israel Deaconess Medical Center, which has 488 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which docetaxel is the first listed.
NCT00004081 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00004081 about?
NCT00004081 is a clinical study titled "Docetaxel in Treating Women With Ovarian Epithelial or Primary Peritoneal Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of docetaxel in treating women who have ovarian epithelial cancer or primary peritoneal cancer that has not responded to previou...
What is the current status of trial NCT00004081?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 1999-07. Estimated completion is 2003-03.
What interventions are being tested in trial NCT00004081?
The interventions under investigation include: docetaxel (DRUG).
Who is sponsoring clinical trial NCT00004081?
This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.